Genitourinary Cancer News

The FDA granted priority review to a supplmemental biologics license application that seeks approval of pembrolizumab for treatment of certain patients with high-risk, nonmuscle-invasive bladder cancer.

There is an association between certain types of commensal urinary microbiome bacteria found in the urinary tract and a clinical response to bacillus Calmette-Guérin immunotherapy for patients with early-stage urothelial bladder cancer, according to results of an investigator-initiated, single institution pilot study presented at Society for Immunotherapy of Cancer Annual Meeting.

Two novel blood assays demonstrated efficacy in detecting various cancer types at different disease stages, according to results of two studies presented at ASCO Breakthrough in Bangkok.

NATIONAL HARBOR, Md. — The combination of sitravatinib and nivolumab induced encouraging clinical activity among patients with advanced urothelial carcinoma who experienced progression after immune checkpoint inhibitor therapy, according to results of a phase 2 study presented at Society for Immunotherapy of Cancer Annual Meeting.

NATIONAL HARBOR, Md. — An investigational bispecific T-cell engager appeared safe and demonstrated some clinical activity among patients with HER2-positive solid tumors, according to phase 1 dose-escalation study data presented at Society for Immunotherapy of Cancer Annual Meeting.

NATIONAL HARBOR, Md. — An investigational anti-CD73 antibody appeared safe and demonstrated promising antitumor activity among patients with advanced cancers, according to phase 1/1b trial data presented at Society for Immunotherapy of Cancer Annual Meeting.

The FDA office that reviews applications for cancer therapies has been renamed and reorganized.

Oncologists acted promptly in response to an FDA restriction last year on the label indication for two immunotherapies, effectively reducing their use by about 50% within 6 months, according to results of a study published in JAMA.

Halle Moore, MD, has been appointed director of breast medical oncology at Cleveland Clinic.

A shortage of the chemotherapy drug vincristine, which is essential to the treatment of most pediatric cancers, has left the oncology community struggling to find short-term solutions while recognizing the need for long-term reform.